Back to News
Market Impact: 0.2
VolitionRx Consensus Price Target Decreased by 17.44% to $13.89
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
VolitionRx's average one-year analyst price target was cut 17.44% to $13.89 per share from $16.83 as of September 11, 2026. The reduction signals a weaker expected valuation outlook for the diagnostics-focused biotech, although the article provides no underlying changes to earnings, clinical, or operating assumptions.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
VNRX-0.40
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October